ZimbabweTuberculosis profile
Population  2015 16 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.7 (0.99–2.5) 11 (6.3–16)
Mortality (HIV+TB only) 6.3 (2.2–13) 40 (14–81)
Incidence  (includes HIV+TB) 38 (28–49) 242 (179–314)
Incidence (HIV+TB only) 26 (17–37) 167 (107–240)
Incidence (MDR/RR-TB)** 1.8 (1–2.5) 12 (6.4–16)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 2.4 (1.1–3.6) 14 (8.3–19) 16 (9.4–23)
Males 2.6 (1.7–3.6) 19 (14–24) 22 (15–28)
Total 5 (3.5–6.5) 33 (27–39) 38 (28–49)
TB case notifications, 2015  
Total cases notified 28 225
Total new and relapse 26 990
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 96%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 54%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 72% (55–97)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.22 (0.09–0.4)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 18 072 70%
          - on antiretroviral therapy 12 924 72%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 100
(690–1 600)
Estimated % of TB cases with MDR/RR-TB 3.2% (1.4–5) 14% (6.9–21)  
% notified tested for rifampicin resistance     9 241
MDR/RR-TB cases tested for resistance to second-line drugs   95
Laboratory-confirmed cases MDR/RR-TB: 468, XDR-TB: 4
Patients started on treatment **** MDR/RR-TB: 433, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 81% 29 653
Previously treated cases registered in 2014 51% 2 363
HIV-positive TB cases, all types, registered in 2014 68% 19 290
MDR/RR-TB cases started on second-line treatment in 2013 59% 351
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 31%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
31% (28–34)
TB financing, 2016  
National TB budget (US$ millions) 28
Funding source:  domestic, 54% international, 46% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data